Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Praecis Continues Cost-Cutting Efforts, Sells Research Facility

Oct. 12, 2005

By Jennifer Boggs

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Oct. 12, 2005

By Jennifer Boggs

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Oct. 12, 2005

By Jennifer Boggs

Praecis Continues Cost-Cutting Efforts, Sells Research Facility

Oct. 12, 2005

By Jennifer Boggs

Vasogen Adds $40M Through Notes Sale For Celacade Work

Oct. 11, 2005

By Jennifer Boggs

Vasogen Adds $40M Through Notes Sale For Celacade Work

Oct. 11, 2005

By Jennifer Boggs

Second Time's The Charm? Acorda Files For $87M IPO

Oct. 7, 2005

By Jennifer Boggs

Second Time's The Charm? Acorda Files For $87M IPO

Oct. 7, 2005

By Jennifer Boggs

Financings roundup: Genomic Health’s IPO gathers $60M for breast cancer test

Oct. 6, 2005

By Jennifer Boggs

Dow Licenses ZFP Technology In Collaboration With Sangamo

Oct. 6, 2005

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...